Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Status: Enrolling
Updated:  3/6/2018
Radiation Oncology , University of Michigan Health System
mi
from
Ann Arbor, MI
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Status: Enrolling
Updated: 3/6/2018
Radiation Oncology , University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI
Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning
Status: Enrolling
Updated:  3/6/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI
Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning
Status: Enrolling
Updated: 3/6/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
Lineberger Cancer Center
mi
from
Chapel Hill, NC
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
Lineberger Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  3/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 3/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Rocky Mountain Cancer Center
mi
from
Denver, CO
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Florida Cancer Specialists
mi
from
Fort Myers, FL
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Ingalls Cancer Research Center
mi
from
Harvey, IL
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Ingalls Cancer Research Center
mi
from
Harvey, IL
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Research Medical Center
mi
from
Kansas City, MO
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Oncology Hematology Care
mi
from
Cincinnati, OH
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Spartanburg Regional Medical Center - Gibbs Cancer Center
mi
from
Spartanburg, SC
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Spartanburg Regional Medical Center - Gibbs Cancer Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated:  3/6/2018
Florida Cancer Specialists North
mi
from
Saint Petersburg, FL
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Status: Enrolling
Updated: 3/6/2018
Florida Cancer Specialists North
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
UCLA Medical Center, Clark Urology Center
mi
from
Los Angeles, CA
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
UCLA Medical Center, Clark Urology Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
mi
from
Philadelphia, PA
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Sunitinib and Capecitabine for First Line Colon Cancer
A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/6/2018
Lombardi Cancer Center-Georgetown University
mi
from
Washington,
Sunitinib and Capecitabine for First Line Colon Cancer
A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/6/2018
Lombardi Cancer Center-Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Georgetown University
mi
from
Washington,
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of Chicago
mi
from
Chicago, IL
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Johns Hopkins
mi
from
Baltimore, MD
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of Michigan
mi
from
Ann Arbor, MI
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Duke University
mi
from
Durham, NC
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Baylor University
mi
from
Houston, TX
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Baylor University
mi
from
Houston, TX
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
NorthShore University HealthSystem
mi
from
Evanston, IL
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated:  3/7/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Investigation of Genetic Determinants of Capecitabine Toxicity
Investigation of Genetic Determinants of Capecitabine Toxicity
Status: Enrolling
Updated: 3/7/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Weill-Cornell Medical College
mi
from
New York, NY
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Yale University
mi
from
New Haven, CT
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/7/2018
University of Chicago
mi
from
Chicago, IL
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/7/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
Status: Enrolling
Updated:  3/7/2018
University of Chicago
mi
from
Chicago, IL
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
Status: Enrolling
Updated: 3/7/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
Status: Enrolling
Updated:  3/7/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
Status: Enrolling
Updated: 3/7/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma
A Phase II Study of Anti-CTLA4 Antibody in Advanced Synovial Sarcoma Patients
Status: Enrolling
Updated:  3/7/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma
A Phase II Study of Anti-CTLA4 Antibody in Advanced Synovial Sarcoma Patients
Status: Enrolling
Updated: 3/7/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation for High-Risk Lymphoma and Myeloma
Status: Enrolling
Updated:  3/8/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation for High-Risk Lymphoma and Myeloma
Status: Enrolling
Updated: 3/8/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
University of Chicago
mi
from
Chicago, IL
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials